Nucleate launch means biotech: the next generation

Latest articles

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

Click the globe for translations.

Nucleate launches nationwide in US to (boldly) empower the next generation of biotech leaders.

Nucleate, a non-profit organisation led by academic trainees and dedicated to empowering future biotech leaders, has announced its launch. Catering to exploding interest among graduate scientific trainees and business students in commercialising biotechnology, the organisation aims to complement traditional institutional ecosystems and streamline company formation to ensure founders can focus on translating cutting-edge science.

Longevity.Technology: Biotech is exploding and Nucleate is set to be a reactor generating more energy for the sector. As we surpass genetic limits and unlock cellular reprogramming, biotech will become key to many industries that impact on longevity, whether that’s synthetic biology, biotech crops, lab-grown meat or environmental biotech. Add it all the sectors directly related to longevity, both medical and industrial, and it’s clear why we need biotech leaders who can foster research, develop their ideas and scale their companies. By identifying future biotech entrepreneurs and arming them with proven training, an exceptional network and funded fellowships, all without the need to give up equity in their companies, Nucleate will remove barriers and help founders concentrate on building transformational technologies.

“The world is facing global-scale challenges in food, water, climate, and disease,” said Reshma Shetty, founder of Ginkgo Bioworks and national advisor to Nucleate. “By making company creation easier and open to all, Nucleate is helping to expand the number of people able to tackle these problems head-on [1].”

Nucleate is now accepting applications for its equity-free, six-month Activator programme; participants are connected with potential co-founders, trained through its structured and rigorous framework and then equipped with an unparalleled network, funded fellowships, legal support, as well as highly-subsidised perks including reagents, lab automation and cloud computing. The Activator programme does not take any equity or other fees for participation.

Over the past three years, Nucleate has validated the Activator model in a pilot program at Harvard University and MIT. So far, the programme has incubated 29 companies that have raised over $24 million in funding to develop new technologies including protein sequencing (Glyphic), drug discovery (Manifold Bio), RNA synthesis (EnPlusOne), and microbial fertiliser (Ivu Biologics). Building on its success, Nucleate has now evolved into a national organisation with an inclusive model for educating biotech leaders.

“We created Nucleate because we noticed a missing layer in the biotech startup ecosystem,” said Soufiane Aboulhouda, Nucleate founding President, Chairman of the Board, and PhD candidate at Harvard Medical School. “With solid proof of concept in Boston, we will now open access to company formation to a new generation of diverse, geographically dispersed, and visionary biotech founders [1].”

Excited by this latest development, Longevity.Technology reached out to Zach Cogan, PhD student at UCSF, EVP of Partnerships and Co-Founder of Nucleate Bay Area, who is actively working in the cellular aging field.

“Decades of research are beginning to coalesce into myriad potential solutions to aging and age-related disease,” Cogan told us. “Nucleate provides infrastructure that will educate and empower the visionary trainees bringing these solutions to market.”

Leadership

Led by over 190 trainees from top scientific and business programs and with participation from over 60 universities and institutes, the organisation is launching in 10 regions across the US (Baltimore, Bay Area, Boston, Houston, Los Angeles, New Haven in Connecticut, New York, Philadelphia, North Carolina’s Research Triangle, and San Diego).

“Translating a scientific discovery into a commercial product is a complex process. I’ve seen this from both sides, as a venture investor and a mentor to biotech entrepreneurs in the academic setting,” said Peter Barrett, Partner at Atlas Venture and Senior Fellow at Harvard Business School. “Nucleate is designed and run by trainees, so it understands what founders need as they transition out of academia. I am proud to advise Nucleate as they launch nationwide to enable future biotech leaders [1].”

[1] https://bit.ly/2XYtJB4

 

Image from Nucleate team.
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Buck Institute awarded $12.7m to join senescence network

NIH award to join SenNet, the Cellular Senescence Network, will enable Buck scientists to identify and characterise senescent cells – recognised as a driver...

Deep learning platform seeks near-term indications of age-related diseases

Arrive co-founder talks combining aging cell biology, drug screening and deep learning technology in the quest to discover novel antiaging targets. Silicon Valley and Singapore-based...

Ovarian aging – it’s time to menopause for thought

It's World Menopause Day – time to focus on the future of ovarian longevity, not dwell in the present. World Menopause Day is held every...

A new approach to reversing tissue aging

Exploring Revel’s enzyme-based approach to breaking down crosslinks and targeting tissue aging. Last year, a startup called Revel Pharmaceuticals emerged from the labs at Yale...